# US 2024/0307397 A1 · Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0307397 A1
- Document ID: US20240307397A1
- Status: Published application
- Kind: A1
- Application number: 18/654,486
- Filed: 2024-05-03
- Published: 2024-09-19
- Earliest claimed: 2021-11-03
- Assignees: Boryung Corporation
- Applicants: Boryung Corporation
- Inventors: Bong-Seog KIM; Hyo Soon JUNG; Kyoung Ryun PARK; Seungho WANG; Seung Hee JUNG; Yoon Sik KIM; Joo Han LEE; Byeongwook JEON; Jongyeon KIM; Tae Min KIM; Seok Jin KIM; Dok Hyun YOON; Yoon Kyung JEON; Ahmad H. MATTOUR; Jorge M. CHAVES
- Web page: https://patentgrep.com/patent/US20240307397A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for preventing or treating peripheral T-cell lymphoma includes a compound represented by formula 1 or pharmaceutically acceptable salts thereof. Specifically, a pharmaceutical composition based on the composition is capable of effectively ameliorating peripheral T-cell lymphoma by decreasing regulatory T cells and increasing CD8+ T cells. The pharmaceutical composition may exhibit anticancer activity against peripheral T-cell lymphoma by decreasing regulatory T cells which suppress immune responses and increasing CD8+ T cells which exhibit anticancer activity. In addition, the pharmaceutical composition is used for the treatment of peripheral T-cell lymphoma due to excellent safety and tolerability.

## Claims

### Claim 1

A pharmaceutical composition for preventing or treating peripheral T-cell lymphoma (PTCL), comprising a compound represented by formula 1 below or pharmaceutically acceptable salts thereof in an amount of 25 mg or more and less than 325 mg as a compound represented by formula 1:

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition comprises the compound represented by above formula 1 or pharmaceutically acceptable salts thereof in an amount of 200 mg or more and less than 325 mg as the compound represented by formula 1.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition comprises the compound represented by above formula 1 or pharmaceutically acceptable salts thereof in an amount of 200 mg as the compound represented by formula 1.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is administered to a subject who has received at least one or more chemotherapies after being diagnosed with peripheral T-cell lymphoma.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is administered once daily for four weeks or more.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is orally administered.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition decreases regulatory T cells (Tregs) and increases CD8+ T cells.

### Claim 8 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the composition is administered once daily for four weeks or more.

### Claim 9 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the composition is orally administered.

### Claim 10 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the composition decreases regulatory T cells (Tregs) and increases CD8+ T cells.

### Claim 11 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the composition is administered once daily for four weeks or more.

### Claim 12 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the composition is orally administered.

### Claim 13 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the composition decreases regulatory T cells (Tregs) and increases CD8+ T cells.

### Claim 14 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the composition is administered once daily for four weeks or more.

### Claim 15 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the composition is orally administered.

### Claim 16 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the composition decreases regulatory T cells (Tregs) and increases CD8+ T cells.
